Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops therapeutic approaches for treating cancer.
Year Established: | |
Funding: | |
Address: | Miramar, FL 33025 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | (954) 443-8610 |
Mail: | |
Company URL: | http://www.altorbioscience.com |
October 22, 2008 Altor BioScience is Awarded Grant from the Bill & Melinda Gates Foundation September 10, 2008 Altor BioScience Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital February 12, 2008 Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech December 20, 2007 Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801 July 25, 2006 Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants March 13, 2006 Altor BioScience Introduces STAR(TM) Multimer Reagents to Measure Disease-Specific Antigen Presentation July 21, 2005 Altor BioScience Awarded SBIR Grant for Manufacturing Therapeutic Antibodies in Transgenic Plants January 19, 2005 Altor BioScience Establishes Collaboration with Leading MGH Investigator to Develop TCR-based Agents to Detect and Treat HIV and HCV Infection September 20, 2004 Altor Bioscience Receives Phase II SBIR Grant for Next-Generation Cancer Therapeutics March 29, 2004 Altor BioScience Reports Advancements in its Soluble T-cell Receptor-Based Technology Programs November 11, 2003 Altor Bioscience Reports Pre-Clinical Results Supporting Utility of Soluble T-Cell Receptor Fusions for Cancer Immunotherapy September 26, 2003 Altor Bioscience Awarded NIH Grant to Expand Screening Program to Identify Orally Available Drugs to Treat Multiple Sclerosis June 1, 2003 Altor Bioscience Receives SBIR Grant from NIAID for Development of Anti-Viral TCR Therapeutics March 18, 2003 Altor Bioscience Issued New U.S. Patent for Innovative T-cell Receptor Technology
Sanderling Ventures,Undisclosed Firm